MarketInOut Stock Screener Log In | Sign Up

MedinCell

PAR • Healthcare • Biotechnology • Quote as of 10/30/2026
MedinCell stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangePAR
Market Capitalization955.49 mln
Float31.70 mln
Earnings Date12/08/2026

Piotroski F-Score

4 / 9
Borderline

1-Year Forecast

35.51
Strong upside

Relative Strength

85 / 100
Strongly outperforming

Debt / Equity

18.74
Extremely leveraged

Pre-Tax Margin

-185%
Severely loss-making

ROE

227
Extraordinary

Business Description

MedinCell is a French biopharmaceutical company founded in 2003 and headquartered in Jacou, France. The company specializes in long-acting injectable medicines built on its proprietary BEPO technology, which allows drugs to be released slowly in the body over extended periods. Its lead commercial product, UZEDY, is already approved for treating schizophrenia and bipolar I disorder in adults, while several other treatments for conditions such as postoperative pain, malaria, and contraception are at various stages of development. MedinCell works alongside partners including AbbVie and IM4TB to bring additional long-acting injectable therapies to market across a range of medical fields.

Key Fundamentals

EPS-0.93
ROE227
RPS0.73
ROIC-69.89
ROA-34.37
Interest Cover-3.87
EBITDA, mln-28.67
EV / EBITDA-27.19
EV / EBIT-25.56
Revenue, mln19.52
EV / Revenue39.93

Quote Details

Last 26.36
Change 0.1 (0.38%)
Open 26.24
Volume 124,087
Turnover 3,270,934
Average Volume 156,666

Financial Ratios

Pre-Tax Profit Margin-185
Leverage Ratio35.27
Current Ratio4.67
Price / Book284
Debt / Equity18.74
Price / Sales41.12

Financial Strength

Altman Z-Score4.99
Piotroski F-Score 4 / 9
1-Year Target Price35.51

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.62% 86 / 100   
1 Month 13.72% 97 / 100   
2 Months 4.44% 83 / 100   
6 Months 0.08% 55 / 100   
1 Year -29.93% 15 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog